Related Experiment Video

Updated: Aug 10, 2026

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
06:22

Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice

Published on: September 17, 2015

Effect of manidipine hydrochloride, a calcium antagonist, on isoproterenol-induced left ventricular hypertrophy

M Yoshiyama1, K Takeuchi, S Kim

  • 1First Department of Internal Medicine, Osaka City University Medical School, Japan.

Japanese Circulation Journal
|April 29, 1998
PubMed

Insights

Manidipine hydrochloride, a calcium antagonist, effectively prevented cardiac hypertrophy and associated gene expression changes in rats. This study highlights its potential in managing heart conditions by inhibiting key molecular pathways.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Cardiac hypertrophy is a significant risk factor for heart failure.
  • Isoproterenol infusion is a common model to induce cardiac hypertrophy in rats.
  • Gene expression of atrial natriuretic peptide (ANP) and extracellular matrix proteins are key indicators of cardiac remodeling.

Purpose of the Study:

  • To investigate the effect of manidipine hydrochloride on isoproterenol-induced cardiac hypertrophy.
  • To analyze the impact of manidipine hydrochloride on the expression of ANP, TGF-beta 1, and extracellular matrix genes.

Main Methods:

  • Rats were induced with cardiac hypertrophy using isoproterenol infusion.
  • Manidipine hydrochloride was administered to assess its protective effects.
  • Left ventricular weight and mRNA levels of specific genes were measured using Northern blot hybridization.

Main Results:

  • Isoproterenol significantly increased left ventricular weight and expression of ANP, collagen type I and III, and fibronectin mRNA.
  • Manidipine hydrochloride treatment prevented the increase in left ventricular weight and normalized the expression of ANP, collagen type I and III, and fibronectin mRNA.
  • Transforming growth factor beta 1 (TGF-beta 1), collagen type IV, and laminin mRNA levels were not significantly altered by isoproterenol or manidipine hydrochloride.

Conclusions:

  • Manidipine hydrochloride effectively prevents cardiac hypertrophy induced by isoproterenol in rats.
  • The drug mitigates changes in the expression of genes related to ANP and interstitial extracellular matrix components.
  • Manidipine hydrochloride shows potential as a therapeutic agent for cardiac hypertrophy and remodeling.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...